CytoDyn Inc NT 10-Q, filed Oct 16, 2023
CytoDyn Inc. (CYDY)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check one): | ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR |
For Period Ended: August 31, 2023 | | ||
☐ Transition Report on Form 10-K | |||
☐ Transition Report on Form 20-F | |||
☐ Transition Report on Form 11-K | |||
☐ Transition Report on Form 10-Q | |||
For the Transition Period Ended: ___________________________________ | | ||
Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
CYTODYN INC.
Full Name of Registrant
Former Name if Applicable
1111 Main Street, Suite 660
Address of Principal Executive Office (Street and Number)
Vancouver, Washington 98660
City, State and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
PART III — NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed).
CytoDyn Inc. (the “Company”) was unable to file timely, without unreasonable effort and expense, its Form 10-Q for the fiscal quarter ended August 31, 2023 (the “Form 10-Q”), because its recently appointed independent registered public accounting firm requires additional time before completing its review of the Company’s financial statements for the fiscal quarter ended August 31, 2023. As noted in Part II(b) above, the Company anticipates that its Form 10-Q will be filed on or before the fifth calendar day following the prescribed due date.
PART IV — OTHER INFORMATION
| (1) | Name and telephone number of person to contact in regard to this notification |
Antonio Migliarese |
| 360 |
| 980-8534 |
(Name) | | (Area Code) | | (Telephone Number) |
| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐ |
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? |
Yes ☐ No ☒
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
| CYTODYN INC | |
| (Name of Registrant as Specified in Charter) | |
| | |
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. | ||
Date | 10/16/2023 | | By | /s/ Antonio Migliarese |
| | | | Antonio Migliarese |
| | | | Chief Financial Officer and Interim President |
2